

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A PRIOR PATENT**

**Docket Number (Optional)** 388512010410

RADEMA	In re Application of: Lawrence M. KAUVAR
	Application No.: 10/713,234
	Filed: November 13, 2003
	For: PROTEIN LOCALIZATION ASSAYS FOR TOXICITY AND ANTIDOTES THERETO
	The owner*, Trellis Bioscience, Inc.  the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,673,554  The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
	and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.
	2. X The undersigned is an attorney or agent of record.
	Lite M. Munagen - August 5, 2004
	Signature 6 Date
	Kate H. Murashige - 29,959
	Typed or printed name
	(858) 720-5112
	Telephone Number
	X Terminal disclaimer fee under 37 CFR 1.20(d) is included.
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.
08/10/2004 SDIRET	A1 00000011 031952 10713234
02 FC:2814	35.00 DA
	·